Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Kobayashi S, Fukushima T, Ueno M, Chuma M, Numata K, Tsuruya K, Arase Y, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Uojima H, Hidaka H, Kusano C, Morimoto M, Maeda S. Kobayashi S, et al. Among authors: matsunaga k. Liver Int. 2024 Jun;44(6):1343-1350. doi: 10.1111/liv.15825. Epub 2024 Mar 4. Liver Int. 2024. PMID: 38436529
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W. Takada J, et al. Among authors: matsunaga k. BMC Res Notes. 2015 Oct 26;8:609. doi: 10.1186/s13104-015-1565-2. BMC Res Notes. 2015. PMID: 26502722 Free PMC article.
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M, Morimoto M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D, Matsunaga K, Okuse C, Suzuki M, Taguri M, Ishibashi T, Numata K, Maeda S, Tanaka K. Kondo M, et al. Among authors: matsunaga k. BMC Cancer. 2019 Oct 15;19(1):954. doi: 10.1186/s12885-019-6198-8. BMC Cancer. 2019. PMID: 31615466 Free PMC article. Clinical Trial.
Safety and Efficacy of Lenvatinib Treatment in Child-Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis.
Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, Maeda S. Ogushi K, et al. Among authors: matsunaga k. Clin Exp Gastroenterol. 2020 Oct 1;13:385-396. doi: 10.2147/CEG.S256691. eCollection 2020. Clin Exp Gastroenterol. 2020. PMID: 33061517 Free PMC article.
Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting.
Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S. Fukushima T, et al. Among authors: matsunaga k. JGH Open. 2021 Dec 17;6(1):29-35. doi: 10.1002/jgh3.12691. eCollection 2022 Jan. JGH Open. 2021. PMID: 35071785 Free PMC article.
A prospective observational cohort study of lenvatinib as initial treatment in patients with BCLC-defined stage B hepatocellular carcinoma.
Kobayashi S, Fukushima T, Ueno M, Moriya S, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Suzuki M, Uojima H, Hidaka H, Kusano C, Suzuki M, Morimoto M. Kobayashi S, et al. Among authors: matsunaga k. BMC Cancer. 2022 May 7;22(1):517. doi: 10.1186/s12885-022-09625-x. BMC Cancer. 2022. PMID: 35525913 Free PMC article.
Risk factors for liver-related mortality of patients with hepatitis C virus after sustained virologic response to direct-acting antiviral agents.
Hattori N, Ikeda H, Watanabe T, Satta Y, Ehira T, Suzuki T, Kiyokawa H, Nakahara K, Takahashi H, Matsunaga K, Matsumoto N, Yasuda H, Suzuki M, Itoh F, Tateishi K. Hattori N, et al. Among authors: matsunaga k. JGH Open. 2022 Aug 26;6(10):685-691. doi: 10.1002/jgh3.12805. eCollection 2022 Oct. JGH Open. 2022. PMID: 36262540 Free PMC article.
Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.
Matsumoto N, Ikeda H, Shigefuku R, Hattori N, Watanabe T, Matsunaga K, Hiraishi T, Tamura T, Noguchi Y, Fukuda Y, Ishii T, Okuse C, Sato A, Suzuki M, Itoh F. Matsumoto N, et al. Among authors: matsunaga k. PLoS One. 2016 Mar 18;11(3):e0151238. doi: 10.1371/journal.pone.0151238. eCollection 2016. PLoS One. 2016. PMID: 26990758 Free PMC article.
1,362 results